Disseminated cancer cells detected by immunocytology in lymph nodes of NSCLC patients are highly prognostic and undergo parallel molecular evolution.
disseminated cancer cell
early metastasis
molecular evolution of NSCLC
prognosis
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
20
07
2022
received:
29
04
2022
accepted:
28
07
2022
pubmed:
24
9
2022
medline:
6
10
2022
entrez:
23
9
2022
Statut:
ppublish
Résumé
In melanoma, immunocytology (IC) after sentinel lymph node disaggregation not only enables better quantification of disseminated cancer cells (DCCs) than routine histopathology (HP) but also provides a unique opportunity to detect, isolate, and analyse these earliest harbingers of metachronous metastasis. Here, we explored lymph node IC in non-small cell lung cancer (NSCLC). For 122 NSCLC patients, 220 lymph nodes (LNs) were split in half and prepared for IC and HP. When both methods were compared, IC identified 22% positive patients as opposed to 4.5% by HP, revealing a much higher sensitivity of IC (p < 0.001). Assessment of all available 2,952 LNs of the same patients by HP uncovered additional patients escaping detection of lymphatic tumour spread by IC alone, consistent with the concept of skip metastasis. A combined lymph node status of IC and complete HP on a larger cohort of patients outperformed all risk factors in multivariable analysis for prognosis (p < 0.001; RR = 2.290; CI 1.407-3.728). Moreover, isolation of DCCs and single-cell molecular characterization revealed that (1) LN-DCCs differ from primary tumours in terms of copy number alterations and selected mutations and (2) critical alterations are acquired during colony formation within LNs. We conclude that LN-IC in NSCLC patients when combined with HP improves diagnostic precision, has the potential to reduce total workload, and facilitates molecular characterization of lymphatically spread cancer cells, which may become key for the selection and development of novel systemic therapies. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
250-263Subventions
Organisme : European Research Council
ID : ERC dash;2012 dash;ADG dash;322602
Pays : International
Informations de copyright
© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Références
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553: 446-454.
SEER*Explorer, National Cancer Institute. 2021; Accessed 25 April 2022] Available from: https://seer.cancer.gov/statistics-network/explorer/application.html?site=47&data_type=4&graph_type=5&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&series=9&race=1&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39-51.
Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell 2017; 168: 670-691.
Passlick B, Izbicki JR, Kubuschok B, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994; 12: 1827-1832.
Izbicki JR, Passlick B, Hosch SB, et al. Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 1996; 112: 623-630.
Osaki T, Oyama T, Inoue M, et al. Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg 2001; 49: 545-551.
Wu J, Ohta Y, Minato H, et al. Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0 cm or less in diameter. Ann Thorac Surg 2001; 71: 1772-1777; discussion 1777-1778.
Gu CD, Osaki T, Oyama T, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and survival. Ann Surg 2002; 235: 133-139.
Tezel C, Ersev AA, Kiral H, et al. The impact of immunohistochemical detection of positive lymph nodes in early stage lung cancer. Thorac Cardiovasc Surg 2006; 54: 124-128.
Yasumoto K, Osaki T, Watanabe Y, et al. Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected nonsmall cell lung cancer: a multicenter prospective study. Ann Thorac Surg 2003; 76: 194-201; discussion 202.
Herpel E, Muley T, Schneider T, et al. A pragmatic approach to the diagnosis of nodal micrometastases in early stage non-small cell lung cancer. J Thorac Oncol 2010; 5: 1206-1212.
Rusch VW, Hawes D, Decker PA, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol 2011; 29: 4313-4319.
Martin LW, D'Cunha J, Wang X, et al. Detection of occult micrometastases in patients with clinical stage I non-small-cell lung cancer: a prospective analysis of mature results of CALGB 9761 (Alliance). J Clin Oncol 2016; 34: 1484-1491.
Izbicki JR, Passlick B, Karg O, et al. Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. Ann Thorac Surg 1995; 59: 209-214.
Wright G, Manser RL, Byrnes G, et al. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 2006; 61: 597-603.
S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. 2018; [Accessed 18 March 2022] Available from: https://www.awmf.org/uploads/tx_szleitlinien/020-007OL_l_S3_Lungenkarzinom_2018-03.pdf
Ulmer A, Dietz K, Hodak I, et al. Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLoS Med 2014; 11: e1001604.
Werner-Klein M, Scheitler S, Hoffmann M, et al. Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun 2018; 9: 595.
Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-312.
Klein CA. Selection and adaptation during metastatic cancer progression. Nature 2013; 501: 365-372.
Klein CA. Cancer progression and the invisible phase of metastatic colonization. Nat Rev Cancer 2020; 20: 681-694.
Ulmer A, Fischer JR, Schanz S, et al. Detection of melanoma cells displaying multiple genomic changes in histopathologically negative sentinel lymph nodes. Clin Cancer Res 2005; 11: 5425-5432.
Latza U, Niedobitek G, Schwarting R, et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 1990; 43: 213-219.
Fehm T, Braun S, Muller V, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006; 107: 885-892.
Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002; 360: 683-689.
Klein CA, Schmidt-Kittler O, Schardt JA, et al. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A 1999; 96: 4494-4499.
Czyz ZT, Hoffmann M, Schlimok G, et al. Reliable single cell array CGH for clinical samples. PLoS One 2014; 9: e85907.
Kubuschok B, Passlick B, Izbicki JR, et al. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 1999; 17: 19-24.
Marchevsky AM, Gupta R, Kusuanco D, et al. The presence of isolated tumor cells and micrometastases in the intrathoracic lymph nodes of patients with lung cancer is not associated with decreased survival. Hum Pathol 2010; 41: 1536-1543.
Rena O, Carsana L, Cristina S, et al. Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg 2007; 32: 863-867.
Rud AK, Boye K, Fodstad Ø, et al. Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer. Diagn Pathol 2016; 11: 50.
Ulmer A, Dietz K, Werner-Klein M, et al. The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival. Eur J Cancer 2018; 91: 1-10.
Riquet M, Hidden G, Debesse B. Direct lymphatic drainage of lung segments to the mediastinal nodes. An anatomic study on 260 adults. J Thorac Cardiovasc Surg 1989; 97: 623-632.
Schirren J, Bergmann T, Beqiri S, et al. Lymphatic spread in resectable lung cancer: can we trust in a sentinel lymph node? Thorac Cardiovasc Surg 2006; 54: 373-380.
Ilic N, Petricevic A, Arar D, et al. Skip mediastinal nodal metastases in the IIIa/N2 non-small cell lung cancer. J Thorac Oncol 2007; 2: 1018-1021.
Baisi A, Raveglia F, De Simone M, et al. Micrometastasis and skip metastasis as predictive factors in non-small-cell lung cancer staging. Eur J Cardiothorac Surg 2013; 43: 1075.
Lee YC, Wu CT, Kuo SW, et al. Significance of extranodal extension of regional lymph nodes in surgically resected non-small cell lung cancer. Chest 2007; 131: 993-999.
Luchini C, Veronese N, Nottegar A, et al. Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. Virchows Arch 2018; 472: 939-947.
Heldwein MB, Doerr F, Schlachtenberger G, et al. Lymphangiosis carcinomatosa independently affects long-term survival of non-small cell lung cancer patients. Surg Oncol 2021; 37: 101611.
Lewis AL, Truong LD, Cagle P, et al. Benign salivary gland tissue inclusion in a pulmonary hilar lymph node from a patient with invasive well-differentiated adenocarcinoma of the lung: a potential misinterpretation for the staging of carcinoma. Int J Surg Pathol 2011; 19: 382-385.
Fellegara G, Carcangiu ML, Rosai J. Benign epithelial inclusions in axillary lymph nodes: report of 18 cases and review of the literature. Am J Surg Pathol 2011; 35: 1123-1133.
Gruber IV, Hartkopf AD, Hahn M, et al. Relationship between hematogenous tumor cell dissemination and cellular immunity in DCIS patients. Anticancer Res 2016; 36: 2345-2351.
Hosseini H, Obradović MMS, Hoffmann M, et al. Early dissemination seeds metastasis in breast cancer. Nature 2016; 540: 552-558.
Hüsemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
Sänger N, Effenberger KE, Riethdorf S, et al. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer 2011; 129: 2522-2526.
Inoue M, Minami M, Shiono H, et al. Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement. J Thorac Cardiovasc Surg 2006; 131: 988-993.
Hamatake D, Yoshida Y, Miyahara S, et al. Surgical outcomes of lung cancer measuring less than 1 cm in diameter. Interact Cardiovasc Thorac Surg 2012; 15: 854-858.
Zhang YK, Chai ZD, Tan LL, et al. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer. World J Surg Oncol 2017; 15: 64.
Schardt JA, Meyer M, Hartmann CH, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005; 8: 227-239.
Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008; 13: 441-453.
Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 2017; 376: 2109-2121.
Wang X, Zhang Y, Nilsson CL, et al. Association of chromosome 19 to lung cancer genotypes and phenotypes. Cancer Metastasis Rev 2015; 34: 217-226.
Mederer T, Elsner F, Robold T, et al. EpCAM-positive disseminated cancer cells in bone marrow impact on survival of early-stage NSCLC patients. Lung Cancer 2022; 167: 73-77.
Travis WD, Al Dayel FHB, Chung JH, et al. WHO Classification of Tumours (5th edn), Volume 5: Thoracic Tumours. IARC Press: Lyon, 2021.
Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 2008; 98: 154-160.
Detection of TP53 mutations by Sanger sequencing (IARC protocol, 2019 update); [Accessed 18 March 2022] Available from: https://tp53.isb-cgc.org/pdf/TP53_SangerSequencing_IARC
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2022. Available from: https://www.R-project.org
Bengtsson H. A Unifying Framework for Parallel and Distributed Processing in R using Futures. R J 2021; 13: 208-227.
Microsoft, Weston S. foreach: Provides Foreach Looping Construct. R package version 1.5.1, 2021. Available from: https://CRAN.R-project.org/package=foreach